Table 2. Clinical outcomes of the INCAN lung cancer patient cohort (n=90).
| % (n/N) | |
|---|---|
| Gender | |
| Female | 63.3 (57/90) |
| Male | 36.7 (33/90) |
| Age (years) | |
| Mean (± S.D.) | 56.2 (14.1) |
| Median | 58.5 |
| Median Age (years) | |
| < 60 | 53.3 (48/90) |
| ≥60 | 46.7 (42/90) |
| Smoking Expossure | |
| Non-smoker | 48.9 (44/90) |
| Smoker | 51.1 (46/90) |
| Tobacco (pack/years) | |
| Mean (± S.D.) | 18.2 (22.9) |
| Median | 10.3 |
| Median of Tobacco (pack/years) | |
| Light smokers (< 10.18) | 50 (23/46) |
| Heavy smokers (≥10.18) | 50 (23/46) |
| Wood-Smoke Exposure | |
| Present | 72 (65/90) |
| Absent | 27.8 (25/90) |
| Asbestos Exposure | |
| Present | 7.8 (7/90) |
| Absent | 92.2 (83/90) |
| Disease Stage | |
| IIIb | 23.3 (21/90) |
| IV | 76.7 (69/90) |
| TNM | |
| TX | 0(0/90) |
| T 0 to 1 | 0(0/90) |
| T2 | 12.2 (11/90) |
| T3 | 15.6 (14/90) |
| T4 | 72.2 (65/90) |
| NX | 72.2 (65/90) |
| N0 | 0 (0/90) |
| N<3 | 0 (0/90) |
| N3 | 15.6 (14/90) |
| N4 | 12.2 (11/90) |
| MX | 0 (0/90) |
| M0 | 23.3 (21/90) |
| M1 | 76.7 (69/90) |
| ECOG PS | |
| 0-1 | 82.2 (74/90) |
| 2-4. | 17.8 (16/90) |
| Histology | |
| Adenocarcinoma | 84.4 (76/90) |
| Epidermoid | 7.8 (7/90) |
| Large Cell Carcinoma | 5.6 (5/90) |
| Undifferentiated and others NSCLC | 2.2 (2/90) |
| Main Histological Pattern Among Adenocarcinoma Patients | |
| Lepidic | 14.5 (11/76) |
| Acinar | 10.5 (8/76) |
| Papilar | 7.9 (6/76) |
| Micropapilar | 1.3 (1/76) |
| Solid | 27.6 (21/76) |
| Other/Not specified | 38.2 (29/76) |
| Received Platinum-Based Chemotherapy | |
| No | 20 (18/90) |
| Yes | 80 (72/90) |
| Therapeutic Response to Platinum-Based Chemotherapy | |
| Complete response | 2.8 (2/72) |
| Partial response | 40.3 (29/72) |
| Stable disease | 40.3 (29/72) |
| Disease Progression | 16.7 (12/72) |
| EGFR-Mutated | |
| Negative | 60 (54/90) |
| Positive | 36.7 (33/90) |
| Undeterminated | 3.3 (3/90) |